Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells

FEMS Immunology and Medical Microbiology

Volumn 38, Issue 2, 2003, Pages 165-172

  Lammers, Karen Manon ^a   Brigidi, Patrizia ^b   Vitali, Beatrice ^b   Gionchetti, Paolo ^a   Rizzello, Fernando ^a   Caramelli, Elisabetta ^b   Matteuzzi, Diego ^b   Campieri, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bacterial DNA; Bifidobacterium; Immune modulation; Inflammatory bowel disease; Lactobacillus

Indexed keywords

BACTERIAL DNA; CYTOKINE; INTERLEUKIN 1 DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROBIOTIC AGENT;

ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL STRAIN; BIFIDOBACTERIUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; ENTERITIS; FECES MICROFLORA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOMODULATION; INGESTION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; MONONUCLEAR CELL; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS THERMOPHILUS; SUPERNATANT;

EID: 0142122636     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00144-5     Document Type: Article

References (23)

1. Shanahan F. Crohn's disease. Lancet. 359:2002;62-69.
2. Duchmann R., Kaiser I., Hermann E., et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102:1995;448-455.
3. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin 10. Science. 289:2000;1352-1354.
4. Van Deventer S.J., Elson C.O., Fedorak R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology. 113:1997;383-389.
5. Shanahan F. Therapeutic manipulation of gut flora. Science. 289:2000;1311-1312.
6. Dunne C., Murphy L., Flynn S., et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek. 76:1999;279-292.
7. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind placebo-controlled trial. Gastroenterology. 119:2000;305-309.
8. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 124(5):2003;1202-1209.
9. Ulisse S., Gionchetti P., D'Alo S., et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am. J. Gastroenterol. 96:2001;2691-2699.
10. Madsen K.L., Doyle J.S., Jewell L.D., et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 116:1999;1107-1114.
11. Madsen K.L., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 121:2001;580-591.
12. Lammers K.M., Helwig U., Swennen E., et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am. J. Gastroenterol. 97:2002;1182-1186.
13. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760.
14. Brigidi P., Vitali B., Swennen E., et al. Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction. Syst. Appl. Microbiol. 23:2000;391-399.
15. Hartemink R., Domenech V.R., Rombouts F.M. LAMVAB a new selective medium for the isolation of lactobacilli from feces. J. Microbiol. Methods. 29:1997;77-84.
16. Hartemink R., Kok B.J., Weenk G.H., et al. Raffinose-Bifidobacterium (RB) agar, a new selective medium for bifidobacteria. J. Microbiol. Methods. 27:1996;33-43.
17. Dave R.I., Shah N.P. Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, and bifidobacteria. J. Dairy Sci. 76:1996;1529-1536.
18. Alander M., Satokari R., Korpela R., et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 65:1999;351-354.
19. Krieg A.M., Yi A.K., Matson S., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
20. 1 mice. J. Immunol. 161:1998;3890-3895.
21. Campieri M., Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology. 116:1999;1246-1249.
22. Rachmilewitz D., Karmeli F., Takabayashi K., et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 122:2002;1428-1441.
23. Agrawal S., Kandimalla E.R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8:2002;114-126.